Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1051MR)

This product GTTS-WQ1051MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1051MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10754MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ6322MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ13812MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ14877MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ14895MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ441MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ11308MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ15719MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VIR-7831
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW